Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Rational Design and Synthesis of Diverse Pyrimidine Molecules Bearing Sulfonamide Moiety as Novel ERK Inhibitors.

Halawa AH, Eskandrani AA, Elgammal WE, Hassan SM, Hassan AH, Ebrahim HY, Mehany ABM, El-Agrody AM, Okasha RM.

Int J Mol Sci. 2019 Nov 8;20(22). pii: E5592. doi: 10.3390/ijms20225592.

2.

Prodigiosins from a marine sponge-associated actinomycete attenuate HCl/ethanol-induced gastric lesion via antioxidant and anti-inflammatory mechanisms.

Abdelfattah MS, Elmallah MIY, Ebrahim HY, Almeer RS, Eltanany RMA, Abdel Moneim AE.

PLoS One. 2019 Jun 13;14(6):e0216737. doi: 10.1371/journal.pone.0216737. eCollection 2019.

3.

(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.

Siddique AB, Ebrahim HY, Akl MR, Ayoub NM, Goda AA, Mohyeldin MM, Nagumalli SK, Hananeh WM, Liu YY, Meyer SA, El Sayed KA.

Nutrients. 2019 Feb 15;11(2). pii: E412. doi: 10.3390/nu11020412.

4.

131 -Oxophorbine protopheophorbide A from Ziziphus lotus as a novel mesenchymal-epithelial transition factor receptor inhibitory lead for the control of breast tumor growth in vitro and in vivo.

Souid S, Elsayed HE, Ebrahim HY, Mohyeldin MM, Siddique AB, Karoui H, El Sayed KA, Essafi-Benkhadir K.

Mol Carcinog. 2018 Nov;57(11):1507-1524. doi: 10.1002/mc.22874. Epub 2018 Jul 18.

PMID:
29978911
5.

Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies.

Elsayed HE, Ebrahim HY, Mohyeldin MM, Siddique AB, Kamal AM, Haggag EG, El Sayed KA.

Nutr Cancer. 2017 Nov-Dec;69(8):1256-1271. doi: 10.1080/01635581.2017.1367936. Epub 2017 Oct 30.

6.

Rationally designed hecogenin thiosemicarbazone analogs as novel MEK inhibitors for the control of breast malignancies.

Elsayed HE, Ebrahim HY, Haggag EG, Kamal AM, El Sayed KA.

Bioorg Med Chem. 2017 Dec 15;25(24):6297-6312. doi: 10.1016/j.bmc.2017.09.033. Epub 2017 Sep 27.

PMID:
29066046
7.

The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.

Ayoub NM, Siddique AB, Ebrahim HY, Mohyeldin MM, El Sayed KA.

Eur J Pharmacol. 2017 Sep 5;810:100-111. doi: 10.1016/j.ejphar.2017.06.019. Epub 2017 Jun 15.

8.

The tobacco cembranoid (1S,2E,4S,7E,11E)-2,7,11-cembratriene-4,6-diol as a novel angiogenesis inhibitory lead for the control of breast malignancies.

Hailat MM, Ebrahim HY, Mohyeldin MM, Goda AA, Siddique AB, El Sayed KA.

Bioorg Med Chem. 2017 Aug 1;25(15):3911-3921. doi: 10.1016/j.bmc.2017.05.028. Epub 2017 May 20.

PMID:
28583806
9.

Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies.

Ebrahim HY, Akl MR, Elsayed HE, Hill RA, El Sayed KA.

J Nat Prod. 2017 Apr 28;80(4):932-952. doi: 10.1021/acs.jnatprod.6b00917. Epub 2017 Feb 28.

PMID:
28245124
10.

(1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies.

Ebrahim HY, Mohyeldin MM, Hailat MM, El Sayed KA.

Bioorg Med Chem. 2016 Nov 15;24(22):5748-5761. doi: 10.1016/j.bmc.2016.09.032. Epub 2016 Sep 13.

11.

The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.

Mohyeldin MM, Akl MR, Ebrahim HY, Dragoi AM, Dykes S, Cardelli JA, El Sayed KA.

Oncotarget. 2016 May 31;7(22):32247-73. doi: 10.18632/oncotarget.8681.

12.

Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds.

Ebrahim HY, El Sayed KA.

Mar Drugs. 2016 Mar 11;14(3). pii: E57. doi: 10.3390/md14030057.

13.

Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met.

Ebrahim HY, Elsayed HE, Mohyeldin MM, Akl MR, Bhattacharjee J, Egbert S, El Sayed KA.

Phytother Res. 2016 Apr;30(4):557-66. doi: 10.1002/ptr.5551. Epub 2016 Jan 6.

14.

The indole alkaloid meleagrin, from the olive tree endophytic fungus Penicillium chrysogenum, as a novel lead for the control of c-Met-dependent breast cancer proliferation, migration and invasion.

Mady MS, Mohyeldin MM, Ebrahim HY, Elsayed HE, Houssen WE, Haggag EG, Soliman RF, El Sayed KA.

Bioorg Med Chem. 2016 Jan 15;24(2):113-22. doi: 10.1016/j.bmc.2015.11.038. Epub 2015 Nov 28.

15.

Araguspongine C induces autophagic death in breast cancer cells through suppression of c-Met and HER2 receptor tyrosine kinase signaling.

Akl MR, Ayoub NM, Ebrahim HY, Mohyeldin MM, Orabi KY, Foudah AI, El Sayed KA.

Mar Drugs. 2015 Jan 8;13(1):288-311. doi: 10.3390/md13010288.

16.

3-O-[N-(p-fluorobenzenesulfonyl)-carbamoyl]-oleanolic acid, a semisynthetic analog of oleanolic acid, induces apoptosis in breast cancer cells.

Akl MR, Elsayed HE, Ebrahim HY, Haggag EG, Kamal AM, El Sayed KA.

Eur J Pharmacol. 2014 Oct 5;740:209-17. doi: 10.1016/j.ejphar.2014.07.011. Epub 2014 Jul 18.

PMID:
25046839
17.

Discovery, optimization, and pharmacophore modeling of oleanolic acid and analogues as breast cancer cell migration and invasion inhibitors through targeting Brk/Paxillin/Rac1 axis.

Elsayed HE, Akl MR, Ebrahim HY, Sallam AA, Haggag EG, Kamal AM, El Sayed KA.

Chem Biol Drug Des. 2015 Feb;85(2):231-43. doi: 10.1111/cbdd.12380. Epub 2014 Jul 16.

PMID:
24954090
18.

Supplemental Content

Loading ...
Support Center